{"id":31193,"date":"2020-02-19T10:01:26","date_gmt":"2020-02-19T09:01:26","guid":{"rendered":"https:\/\/packaging-journal.de\/?p=31193"},"modified":"2021-04-13T16:35:02","modified_gmt":"2021-04-13T14:35:02","slug":"gerresheimer-financial-year-2019","status":"publish","type":"post","link":"https:\/\/packaging-journal.de\/en\/gerresheimer-geschaeftsjahr-2019\/","title":{"rendered":"Gerresheimer closes financial year 2019 successfully"},"content":{"rendered":"

Last year, Gerresheimer laid important foundations for future profitable growth. The company is focussing strongly on new segments such as complete solutions for biotech drugs, innovations, more sales in fast-growing markets and investments.<\/p>\n

\u201eTogether, we laid the foundations in 2019 to make Gerresheimer fit for the future and put the company on a clear growth path. We have actively worked on the topics of innovation, excellence, customer and employee focus and will continue to do so. We have invested a record amount in growth, capacity, process optimisation and digitalisation. Our clear goal: sustainable and profitable growth,\u201c commented Dietmar Siemssen<\/strong>, Chief Executive Officer of Gerresheimer AG.<\/p><\/blockquote>\n

In 2019, the largest investment programme<\/strong> in the company's history: \u00a0185 million euros<\/strong> was invested, with a focus on growth projects, capacity expansion, process optimisation and digitalisation. This included the further Expansion of inhaler production<\/strong> at the plant in Horsovsky Tyn in the Czech Republic, the construction of the new plants in North Macedonia and Brazil<\/strong> as well as the expansion of the product portfolio and the creation of additional production capacities.<\/p>\n

Two new Plants in China and India<\/strong> for the production of pharmaceutical primary packaging made of plastic were inaugurated. In addition, the Innovation and technology centre for glass in North America<\/strong> in the course of a customer event.<\/p>

\"\"<\/a><\/div><\/div>\n

In the 2019 financial year, the Syringe business very positive<\/strong> developed favourably. Sales revenues with pharmaceutical primary packaging made of plastic<\/strong> increased in South America and Asia in particular. Sales revenue from primary packaging made of glass developed well, driven in particular by the very good Demand for high-quality cosmetics packaging<\/strong>. In the area of cosmetics packaging, the company is increasingly focussing on Sustainable solutions<\/strong>, in particular through the Use of recycled glass and plastic<\/strong>.\u00a0<\/span><\/p>\n

Sales revenues with Injection vials, ampoules and cartridges<\/strong> in Europe and Asia increased significantly. In North America, sales of these products declined slightly due to lower demand from a major customer. In the Advanced Technologies division<\/strong> the micropump for the treatment of Parkinson's disease was successfully launched on the market. A new project for the use of the micropump for patients with heart failure was acquired and is currently being implemented.<\/p>